436 related articles for article (PubMed ID: 17652820)
1. New iron chelators in anthracycline-induced cardiotoxicity.
Kaiserová H; Simunek T; Sterba M; den Hartog GJ; Schröterová L; Popelová O; Gersl V; Kvasnicková E; Bast A
Cardiovasc Toxicol; 2007; 7(2):145-50. PubMed ID: 17652820
[TBL] [Abstract][Full Text] [Related]
2. Protection by flavonoids against anthracycline cardiotoxicity: from chemistry to clinical trials.
Bast A; Haenen GR; Bruynzeel AM; Van der Vijgh WJ
Cardiovasc Toxicol; 2007; 7(2):154-9. PubMed ID: 17652822
[TBL] [Abstract][Full Text] [Related]
3. Cardioprotective effects of a novel iron chelator, pyridoxal 2-chlorobenzoyl hydrazone, in the rabbit model of daunorubicin-induced cardiotoxicity.
Sterba M; Popelová O; Simunek T; Mazurová Y; Potácová A; Adamcová M; Kaiserová H; Ponka P; Gersl V
J Pharmacol Exp Ther; 2006 Dec; 319(3):1336-47. PubMed ID: 17003229
[TBL] [Abstract][Full Text] [Related]
4. Pyridoxal isonicotinoyl hydrazone (PIH) and its analogs as protectants against anthracycline-induced cardiotoxicity.
Simunek T; Sterba M; Popelova O; Kaiserova H; Potacova A; Adamcova M; Mazurova Y; Ponka P; Gersl V
Hemoglobin; 2008; 32(1-2):207-15. PubMed ID: 18274998
[TBL] [Abstract][Full Text] [Related]
5. Antioxidant defense against anthracycline cardiotoxicity by metallothionein.
Kang YJ
Cardiovasc Toxicol; 2007; 7(2):95-100. PubMed ID: 17652812
[TBL] [Abstract][Full Text] [Related]
6. Iron chelation-afforded cardioprotection against chronic anthracycline cardiotoxicity: a study of salicylaldehyde isonicotinoyl hydrazone (SIH).
Sterba M; Popelová O; Simůnek T; Mazurová Y; Potácová A; Adamcová M; Guncová I; Kaiserová H; Palicka V; Ponka P; Gersl V
Toxicology; 2007 Jun; 235(3):150-66. PubMed ID: 17459556
[TBL] [Abstract][Full Text] [Related]
7. Iron is not involved in oxidative stress-mediated cytotoxicity of doxorubicin and bleomycin.
Kaiserová H; den Hartog GJ; Simůnek T; Schröterová L; Kvasnicková E; Bast A
Br J Pharmacol; 2006 Dec; 149(7):920-30. PubMed ID: 17031387
[TBL] [Abstract][Full Text] [Related]
8. An introduction to the metabolic determinants of anthracycline cardiotoxicity.
Menna P; Recalcati S; Cairo G; Minotti G
Cardiovasc Toxicol; 2007; 7(2):80-5. PubMed ID: 17652809
[TBL] [Abstract][Full Text] [Related]
9. Genotyping the risk of anthracycline-induced cardiotoxicity.
Deng S; Wojnowski L
Cardiovasc Toxicol; 2007; 7(2):129-34. PubMed ID: 17652817
[TBL] [Abstract][Full Text] [Related]
10. Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism.
Cusack BJ; Gambliel H; Musser B; Hadjokas N; Shadle SE; Charlier H; Olson RD
Cancer Chemother Pharmacol; 2006 Oct; 58(4):517-26. PubMed ID: 16555089
[TBL] [Abstract][Full Text] [Related]
11. Iron chelation by clinically relevant anthracyclines: alteration in expression of iron-regulated genes and atypical changes in intracellular iron distribution and trafficking.
Xu X; Sutak R; Richardson DR
Mol Pharmacol; 2008 Mar; 73(3):833-44. PubMed ID: 18029550
[TBL] [Abstract][Full Text] [Related]
12. Long-term and short-term models for studying anthracycline cardiotoxicity and protectors.
Robert J
Cardiovasc Toxicol; 2007; 7(2):135-9. PubMed ID: 17652818
[TBL] [Abstract][Full Text] [Related]
13. Prevention of anthracycline cardiotoxicity by iron chelation.
Hershko C; Pinson A; Link G
Acta Haematol; 1996; 95(1):87-92. PubMed ID: 8604592
[TBL] [Abstract][Full Text] [Related]
14. Novel antioxidants in anthracycline cardiotoxicity.
Hideg K; Kálai T
Cardiovasc Toxicol; 2007; 7(2):160-4. PubMed ID: 17652823
[TBL] [Abstract][Full Text] [Related]
15. The role of iron and iron chelators in anthracycline cardiotoxicity.
Hershko C; Link G; Tzahor M; Pinson A
Leuk Lymphoma; 1993 Oct; 11(3-4):207-14. PubMed ID: 8260895
[TBL] [Abstract][Full Text] [Related]
16. Molecular pharmacology of the interaction of anthracyclines with iron.
Xu X; Persson HL; Richardson DR
Mol Pharmacol; 2005 Aug; 68(2):261-71. PubMed ID: 15883202
[TBL] [Abstract][Full Text] [Related]
17. Procyanidins produce significant attenuation of doxorubicin-induced cardiotoxicity via suppression of oxidative stress.
Li W; Xu B; Xu J; Wu XL
Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):192-7. PubMed ID: 19143757
[TBL] [Abstract][Full Text] [Related]
18. Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings?
Lenčová-Popelová O; Jansová H; Jirkovský E; Bureš J; Jirkovská-Vávrová A; Mazurová Y; Reimerová P; Vostatková L; Adamcová M; Hroch M; Pokorná Z; Kovaříková P; Šimůnek T; Štěrba M
Toxicology; 2016 Nov; 372():52-63. PubMed ID: 27816693
[TBL] [Abstract][Full Text] [Related]
19. Human heart cytosolic reductases and anthracycline cardiotoxicity.
Mordente A; Meucci E; Martorana GE; Giardina B; Minotti G
IUBMB Life; 2001 Jul; 52(1-2):83-8. PubMed ID: 11795600
[TBL] [Abstract][Full Text] [Related]
20. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron.
Simůnek T; Stérba M; Popelová O; Adamcová M; Hrdina R; Gersl V
Pharmacol Rep; 2009; 61(1):154-71. PubMed ID: 19307704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
